N/A N=86 A Couple Support Intervention for Prostate Cancer
Prostate Cancer
Primary: EPIC (Expanded Prostate Cancer Index Composite), Sexual Bother Subscale — 24.11; 20.45; 44.092; 26.3889 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=16 A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013)
Overactive Bladder
Primary: Area Under the Concentration Time Curve From 0 to Infinity (AUC0-∞) After a Single Oral Dose of Vibegron 100 mg — 4.10; 3.23 uM•hr
Phase 1 N=52 Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC
Non Small Cell Lung Cancer
Primary: Cmax of Simvastatin — 24.54; 18.65 ng/mL
N/A N=63 Plastic vs. Covered Metal vs. Uncovered Metal Biliary Stents for the Management of Malignant Biliary Obstruction
Pancreatic Cancer
Primary: Assess the Occlusion Rates, Attempted Surgical Resection or Death of Plastic, Covered, and Uncovered Biliary Stents in Patients Presenting With Malignant Biliary…
Phase 2 N=41 Capecitabine and Temozolomide for Neuroendocrine Cancers
Neuroendocrine Tumors
Primary: Number of Participants With Partial Response (PR) — 9 participants
Phase 2 N=37 A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer
Pancreatic Cancer
Primary: Number of Subjects Who Experience Dose Limiting Toxicities (DLTs)
Phase 2 N=32 Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar
Pancreatic Cancer Stage IVA
Primary: Conversion Rate of Inoperable to Operable
N/A N=80 Mild Compression Sock for Control of Lower Extremity Edema in Individuals With Diabetes
Edema
Primary: Cutaneous Water Content — -1.1; -.82; -0.99; -2.1 percentage change in dielectric constant — p=>0.05
Phase 3 N=1,987 A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
Colorectal Cancer
Primary: Disease-free Survival — 656; 603 Participants — p=0.053
Phase 4 N=25 Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?
Type 2 Diabetes Mellitus
Primary: Plasma 15-epi-lipoxin A4 — 1.05; 1.08 ng/ml
Phase 4 N=76 Combining Placing a Synera Patch With Propofol/Lidocaine Mixture to Decrease Pain With IV Propofol Injection
Pain on IV Injection of Propofol.
Primary: Number of Children in Each Group Who Don't Feel Pain or Have Mild Pain on Propofol Injection. — 29; 19 participants
Phase 3 N=261 Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis
Uveitis
Primary: Time to Treatment Failure on or After Week 2 — 8.3; NA; 5.6; NA months — p=0.004
Phase 2 N=70 Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Primary: Response Rate (RR) After 6 Cycles of Therapy Using the Proposed International Myeloma Working Group Uniform Response Criteria — 86.7; 71.4 percentage of participants
Phase 2 N=109 A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
Breast Cancer
Primary: Median Time to Disease Progression — 171; 171 Days
Phase 4 N=53 The Effect of Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets Compared to Placebo in Subjects Suffering From the Common Cold or Influenza.
Common Cold
Primary: Symptom Severity Assessment at 15 Minutes — 10.66; 10.64; -1.11; -1.13 Score on scale — p=0.9473